Corbus Pharmaceuticals Hldgs Inc CRBP

$4.05 -0.08 (-1.94%)

Valuation

Market cap
75,618,000
Revenue TTM
$0
Net income TTM
$-78,540,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
372,900
Avg volume
1,006,868
Day's range
$3.93 – $4.08
Shares out
18,671,000
Stochastic %K
9%
Beta
2.63
Analysts
Strong Sell
Price target
$35.89

Price

Company profile

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The...

Show more

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 963 0100
Website
https://www.corbuspharma.com
Address
500 River Ridge Drive, Norwood, United States

Latest news

Stocktwits

birdmine Oct 26, 2:45 PM
$CRBP I don’t think stones drop as fast as this shit!!
0 replies
1978280Z Oct 23, 2:00 PM
$CRBP I am getting Passage Bio vibes from this stock.
0 replies
birdmine Oct 23, 1:54 PM
$CRBP if Dante’s Inferno was a stock…
0 replies
Merlintrader Oct 22, 9:34 PM
$CRBP Latest company news, Oct 22, 2026: Corbus will present late-breaking CRB-913 data from the Phase 1b CANYON-1 obesity study as a poster at ObesityWeek 2026 on November 15 (2:30-3:30 p.m. ET) in National Harbor, MD. Full hub (CRB-701, CRB-913, cash): https://www.merlintrader.com/corbus-pharmaceuticals-stock-hub/ Not investment advice.
0 replies
birdmine Oct 22, 7:04 PM
$CRBP I don’t see it happening, but if this bounces to the mid teens to low 20’s I advise everyone to jump ship.
1 replies
birdmine Oct 22, 3:08 PM
$CRBP WTF?!?!?!?!
0 replies
focafoca99 Oct 22, 12:45 PM
$CRBP intends to present late-breaking CRB-913 data at Obesity Week 2026 in November. https://www.rapidticker.com/news/crbp-corbus-pharmaceuticals-to-present-late-f2bd80
0 replies
renata1 Oct 22, 2:15 AM
$CRBP Received FDA clearance for its TEMPO-1 registrational study in second-line oropharyngeal cancer, and the first patient was dosed on September 29, 2026. This is a significant development milestone...
0 replies